// App-Quantinova.ai

68 : Ubrogepant is effective in the acute treatment of migraine with mild pain

Researchers

Presenter

  • Richard Lipton

Principal Investigators

  • David Dodick

  • Peter Goadsby

  • Rami Burstein

  • Aubrey Adams

  • Jeff Lai

  • Sung Yu

  • Michelle Finnegan

  • Joel Trugman

Medical Centers

  • Albert Einstein College of Medicine, Bronx, NY, United States Minor Outlying Islands

  • Montefiore Headache Center, Bronx, NY, United States Minor Outlying Islands

  • Mayo Clinic, Rochester, United States Minor Outlying Islands

  • NIHR-Wellcome Trust King’s Clinical Research Facility, London, United Kingdom

  • Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, United States Minor Outlying Islands

  • AbbVie, Irvine, CA, United States Minor Outlying Islands

  • AbbVie, Irvine, CA, United States Minor Outlying Islands

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Migraine

Biomarkers

  • N/A

Drug/Treatment

  • Ubrogepant

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT02873221

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved